{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:21:57Z","timestamp":1789647717685,"version":"4.0.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 114\\u20132314-B-016\\u2013054-MY3"],"award-info":[{"award-number":["NSTC 114\\u20132314-B-016\\u2013054-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 113\\u20132314-B-016\\u2013035"],"award-info":[{"award-number":["NSTC 113\\u20132314-B-016\\u2013035"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 112\\u20132314-B-016\\u2013025"],"award-info":[{"award-number":["NSTC 112\\u20132314-B-016\\u2013025"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003559","name":"Ministry of National Defense","doi-asserted-by":"publisher","award":["NSTC 111\\u20132314\\u2013B\\u2013195\\u2013020\\u2013MY3"],"award-info":[{"award-number":["NSTC 111\\u20132314\\u2013B\\u2013195\\u2013020\\u2013MY3"]}],"id":[{"id":"10.13039\/501100003559","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003559","name":"Ministry of National Defense","doi-asserted-by":"publisher","award":["MND-MAB-D-112128"],"award-info":[{"award-number":["MND-MAB-D-112128"]}],"id":[{"id":"10.13039\/501100003559","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003559","name":"Ministry of National Defense","doi-asserted-by":"publisher","award":["PC11107-5490"],"award-info":[{"award-number":["PC11107-5490"]}],"id":[{"id":"10.13039\/501100003559","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejps.2025.107417","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T16:17:19Z","timestamp":1765988239000},"page":"107417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["ASIC3\u2013PLCG1 axis\u2013driven macropinocytosis promotes osimertinib drug-tolerant persistence in malignant pleural effusion\u2013associated NSCLC"],"prefix":"10.1016","volume":"217","author":[{"given":"Wen\u2010Chien","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh-Yung","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Ying","family":"Changchien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Feng","family":"Chian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9783-5423","authenticated-orcid":false,"given":"Chen-Liang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2025.107417_bib0001","doi-asserted-by":"crossref","unstructured":"Addala, D.N., Kanellakis, N.I., Bedawi, E.O., Dong, T., Rahman, N.M., 2022. Malignant pleural effusion: updates in diagnosis, management and current challenges. 12.","DOI":"10.3389\/fonc.2022.1053574"},{"key":"10.1016\/j.ejps.2025.107417_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15205079","article-title":"New generations of tyrosine kinase inhibitors in treating NSCLC with oncogene addiction: strengths and limitations","volume":"15","author":"Attili","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejps.2025.107417_bib0003","first-page":"1622","article-title":"Bacterial persistence as a phenotypic switch","volume":"305","author":"Balaban","year":"2004","journal-title":"Science 1979"},{"key":"10.1016\/j.ejps.2025.107417_bib0004","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-71623-9","article-title":"Acid-sensing ion channel 3 is a new potential therapeutic target for the control of glioblastoma cancer stem cells growth","volume":"14","author":"Balboni","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejps.2025.107417_bib0005","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(00)74210-3","article-title":"Treatment of staphylococcal infections with penicillin by intermittent sterilisation","volume":"244","author":"Bigger","year":"1944","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2025.107417_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.979154","article-title":"Tumor acidity: from hallmark of cancer to target of treatment","volume":"12","author":"Bogdanov","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejps.2025.107417_bib0007","article-title":"Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients","volume":"7","author":"Chabon","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejps.2025.107417_bib0008","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrc3775","article-title":"Non-small-cell lung cancers: a heterogeneous set of diseases","volume":"14","author":"Chen","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejps.2025.107417_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020504","article-title":"Mechanisms of acquired resistance and tolerance to EGFR targeted therapy in non-small cell lung cancer","volume":"15","author":"Chhouri","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejps.2025.107417_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112613","article-title":"Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer","volume":"14","author":"Delahaye","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejps.2025.107417_bib0011","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1158\/0008-5472.CAN-14-3167","article-title":"Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 Is associated with increased dependence on RAS signaling in preclinical models","volume":"75","author":"Eberlein","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2025.107417_bib0012","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s42003-023-05087-4","article-title":"Physiologically relevant acid-sensing ion channel (ASIC) 2a\/3 heteromers have a 1:2 stoichiometry","volume":"6","author":"Fischer","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejps.2025.107417_bib0013","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12931-024-02684-7","article-title":"Malignant pleural effusion: current understanding and therapeutic approach","volume":"25","author":"Gonnelli","year":"2024","journal-title":"Respir. Res."},{"key":"10.1016\/j.ejps.2025.107417_bib0014","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ccell.2017.07.002","article-title":"Repression of stress-induced line-1 expression protects cancer cell subpopulations from lethal drug exposure","volume":"32","author":"Guler","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejps.2025.107417_bib0015","first-page":"809","article-title":"Lung cancer: current diagnosis and treatment","volume":"106","author":"Hammerschmidt","year":"2009","journal-title":"Deutsches \u00c4rzteblatt Int."},{"key":"10.1016\/j.ejps.2025.107417_bib0016","first-page":"1284","article-title":"Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism","volume":"8","author":"Helmlinger","year":"2002","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.ejps.2025.107417_bib0017","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejps.2025.107417_bib0018","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0002-9610(89)90623-5","article-title":"Pleural fluid pH: diagnostic, therapeutic, and prognostic value","volume":"154","author":"Houston","year":"1987","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.ejps.2025.107417_bib0019","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13045-022-01347-8","article-title":"The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis","volume":"15","author":"Huang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejps.2025.107417_bib0020","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"Janne","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2025.107417_bib0021","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1021\/cn9000186","article-title":"Synthesis, structure-activity relationship, and pharmacological profile of analogs of the ASIC-3 inhibitor A-317567","volume":"1","author":"Kuduk","year":"2010","journal-title":"ACS. Chem. Neurosci."},{"key":"10.1016\/j.ejps.2025.107417_bib0022","series-title":"Proceedings of the National Academy of Sciences of the United States of America","first-page":"7665","article-title":"Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib","volume":"102","author":"Kwak","year":"2005"},{"key":"10.1016\/j.ejps.2025.107417_bib0023","doi-asserted-by":"crossref","unstructured":"Lee, E., Yeo, S.-Y., Lee, K.-W., Lee, J.A., Kim, K.K., Kim, S.-H., 2020. New screening system using Twist1 promoter activity identifies dihydrorotenone as a potent drug targeting cancer-associated fibroblasts. 10, 1\u201314.","DOI":"10.1038\/s41598-020-63996-4"},{"key":"10.1016\/j.ejps.2025.107417_bib0024","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The warburg effect: how does it benefit cancer Cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends. Biochem. Sci."},{"key":"10.1016\/j.ejps.2025.107417_bib0025","doi-asserted-by":"crossref","unstructured":"Lojo-Rodr\u00edguez, I., Botana-Rial, M., Gonz\u00e1lez-Montaos, A., Leiro-Fern\u00e1ndez, V., Gonz\u00e1lez-Pi\u00f1eiro, A., Ramos-Hern\u00e1ndez, C., Fern\u00e1ndez-Villar, A., 2024. Clinical and molecular features of malignant pleural effusion in non-small cell lung cancer (NSCLC) of a caucasian population. 60, 1804.","DOI":"10.3390\/medicina60111804"},{"key":"10.1016\/j.ejps.2025.107417_bib0026","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2025.107417_bib0027","first-page":"10","article-title":"T790M and acquired resistance of EGFR TKI: a literature review of clinical reports","volume":"3","author":"Ma","year":"2011","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.ejps.2025.107417_bib0028","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15205009","article-title":"Resistance of lung cancer to EGFR-specific kinase inhibitors: activation of bypass pathways and endogenous mutators","volume":"15","author":"Marrocco","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejps.2025.107417_bib0029","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2147\/CMAR.S95663","article-title":"Management of malignant pleural effusion: challenges and solutions","volume":"9","author":"Penz","year":"2017","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.ejps.2025.107417_bib0030","doi-asserted-by":"crossref","unstructured":"Piggott, L.M., Hayes, C., Greene, J., Fitzgerald, D.B., 2024. Malignant pleural disease. 19, 230145.","DOI":"10.1183\/20734735.0145-2023"},{"key":"10.1016\/j.ejps.2025.107417_bib0031","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10555-019-09792-7","article-title":"Causes, consequences, and therapy of tumors acidosis","volume":"38","author":"Pillai","year":"2019","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ejps.2025.107417_bib0032","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1093\/annonc\/mdv319","article-title":"EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients","volume":"26","author":"Planchard","year":"2015","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.ejps.2025.107417_bib0033","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41571-023-00815-5","article-title":"Drug-tolerant persister cells in cancer: the cutting edges and future directions","volume":"20","author":"Pu","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejps.2025.107417_bib0034","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41392-020-00313-5","article-title":"Emerging role of tumor cell plasticity in modifying therapeutic response","volume":"5","author":"Qin","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.ejps.2025.107417_bib0035","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10690","article-title":"Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells","volume":"7","author":"Ramirez","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejps.2025.107417_bib0036","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fendo.2017.00261","article-title":"Macropinocytosis: a metabolic adaptation to nutrient stress in cancer","volume":"8","author":"Recouvreux","year":"2017","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejps.2025.107417_bib0037","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12915-022-01340-0","article-title":"Proton export upregulates aerobic glycolysis","volume":"20","author":"Russell","year":"2022","journal-title":"BMC. Biol."},{"key":"10.1016\/j.ejps.2025.107417_bib0038","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","article-title":"Cancer drug-tolerant persister cells: from biological questions to clinical opportunities","volume":"24","author":"Russo","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejps.2025.107417_bib0039","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1038\/s41598-019-40519-4","article-title":"Primary lung cancer samples cultured under microenvironment-mimetic conditions enrich for mesenchymal stem-like cells that promote metastasis","volume":"9","author":"Saforo","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejps.2025.107417_bib0040","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ejps.2025.107417_bib0041","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3892\/ijo.2023.5584","article-title":"Acidosis promotes the metastatic colonization of lung cancer via remodeling of the extracellular matrix and vasculogenic mimicry","volume":"63","author":"Shie","year":"2023","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejps.2025.107417_bib0042","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/j.1349-7006.2011.01887.x","article-title":"Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports","volume":"102","author":"Shukuya","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejps.2025.107417_bib0043","first-page":"6540","article-title":"Establishment and identification of human primary lung cancer cell culture in vitro","volume":"8","author":"Si","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.ejps.2025.107417_bib0044","doi-asserted-by":"crossref","DOI":"10.3390\/medicina55080490","article-title":"Malignant pleural effusion and its current management: a review","volume":"55","author":"Skok","year":"2019","journal-title":"Medicina"},{"key":"10.1016\/j.ejps.2025.107417_bib0045","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12943-018-0778-0","article-title":"Third generation EGFR TKIs: current data and future directions","volume":"17","author":"Tan","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejps.2025.107417_bib0046","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejps.2025.107417_bib0047","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12885-020-6593-1","article-title":"Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy","volume":"20","author":"Tokudome","year":"2020","journal-title":"BMC. Cancer"},{"key":"10.1016\/j.ejps.2025.107417_bib0048","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.7150\/thno.34070","article-title":"Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer","volume":"9","author":"Tong","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.ejps.2025.107417_bib0049","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2009.11.022","article-title":"Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC","volume":"17","author":"Turke","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejps.2025.107417_bib0050","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bcp.2018.11.004","article-title":"Dormant, quiescent, tolerant and persister cells: four synonyms for the same target in cancer","volume":"162","author":"Vallette","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107417_bib0051","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12964-024-01762-z","article-title":"ASIC3-activated key enzymes of de novo lipid synthesis supports lactate-driven EMT and the metastasis of colorectal cancer cells","volume":"22","author":"Wan","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejps.2025.107417_bib0052","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.21037\/jtd-2024-1999","article-title":"Malignant pleural effusion is a negative prognostic factor for immunotherapy outcomes in non-small cell lung cancer: a single-center retrospective study","volume":"17","author":"Wang","year":"2025","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.ejps.2025.107417_bib0053","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12943-018-0777-1","article-title":"Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer","volume":"17","author":"Wu","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejps.2025.107417_bib0054","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1161\/01.RES.0000238388.79295.4c","article-title":"Sustained currents through ASIC3 ion channels at the modest pH changes that occur during myocardial ischemia","volume":"99","author":"Yagi","year":"2006","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejps.2025.107417_bib0055","article-title":"Malignant pleural effusion diagnosis and therapy","volume":"18","author":"Yang","year":"2023","journal-title":"Open. Life Sci."},{"key":"10.1016\/j.ejps.2025.107417_bib0056","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1097\/JTO.0b013e31829f691f","article-title":"High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact?","volume":"8","author":"Ye","year":"2013","journal-title":"J. Thorac. Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"10.1016\/j.ejps.2025.107417_bib0057","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41392-019-0099-9","article-title":"The emerging treatment landscape of targeted therapy in non-small-cell lung cancer","volume":"4","author":"Yuan","year":"2019","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.ejps.2025.107417_bib0058","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","article-title":"Non-small cell lung cancer: current treatment and future advances","volume":"5","author":"Zappa","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.ejps.2025.107417_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104483","article-title":"Redox signaling in drug-tolerant persister cells as an emerging therapeutic target","volume":"89","author":"Zhang","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejps.2025.107417_bib0060","article-title":"Current status of and progress in the treatment of malignant pleural effusion of lung cancer","volume":"12","author":"Zhao","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejps.2025.107417_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2025.152107","article-title":"Cell cycle dynamics analysis of drug-tolerant persister cells in non-small cell lung cancer","volume":"775","author":"Zhou","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejps.2025.107417_bib0062","doi-asserted-by":"crossref","first-page":"33403","DOI":"10.18632\/oncotarget.23607","article-title":"Cancer stem cells in progression of colorectal cancer","volume":"9","author":"Zhou","year":"2017","journal-title":"Oncotarget"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725004142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725004142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:20:38Z","timestamp":1773940838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098725004142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":62,"alternative-id":["S0928098725004142"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107417","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ASIC3\u2013PLCG1 axis\u2013driven macropinocytosis promotes osimertinib drug-tolerant persistence in malignant pleural effusion\u2013associated NSCLC","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107417","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107417"}}